Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 5

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 5
---
 Shares held by persons described
in items (a) through (d) of section 8.1(2) of Multilateral Instrument 61-101 —Protection of Minority Security Holders in Special Transactions (“MI 61-101”). See “Canadian Securities Law Matters—Multilateral Instrument 61-101” for more
information.

We are also seeking approval of (i) the Compensation Resolution by the affirmative vote of a majority of the votes cast
by Shareholders present in person (virtually) or represented by proxy at the Special Meeting, (ii) the Liquidation Resolution by the affirmative vote of not less than 66⁄% of the votes cast by Shareholders present in person (virtually) or represented by proxy at the Special Meeting, and (ii) the Liquidator Resolution by the affirmative vote of not less than 66⁄% of the votes cast by Shareholders present in person (virtually) or represented by proxy at the Special Meeting. The Board unanimously recommends that Shareholders
vote FOR the Compensation Resolution, FOR the Liquidation Resolution and FOR the Liquidator Resolution. The completion of the Arrangement is not conditional upon the approval of the Compensation Resolution, the Liquidation
Resolution or the Liquidator Resolution.

Whether or not you plan to attend the Special Meeting, it is important that you use this
opportunity to take part in the affairs of the Company by voting on the business to come before the Special Meeting. We ask that you submit a proxy or voting instruction form to have your securities voted in advance of the Special Meeting by using
one of the methods described in this Circular and Proxy Statement. After reading the enclosed Circular and Proxy Statement, please promptly mark, sign, date and return the enclosed proxy or voting instruction form as instructed to ensure that your
Common Shares will be represented. Regardless of the number of Common Shares you own, your careful consideration of, and vote on, the matters before our Shareholders is important.

The enclosed Circular and Proxy Statement describes the Agreement, the Arrangement and related agreements and provides specific information
concerning the Special Meeting. In addition, you may obtain information about us from documents filed with the SEC. We urge you to read the entire Circular and Proxy Statement, including the annexes, carefully, as it sets forth the details of the
Agreement and other important information related to the Arrangement.

We look forward to seeing you at the Special Meeting.

3

Sincerely yours,

Steve Forte

President, Chief Executive Officer and Chief
Financial